# C_2014391EN.01001501.xml

| 6.11.2014 | EN | Official Journal of the European Union | C 391/15 |
| --- | --- | --- | --- |

6.11.2014

EN

Official Journal of the European Union

C 391/15

---

Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the second half of 2013

2014/C 391/04

Subcommittee I on the free movement of goods

Subcommittee I on the free movement of goods

To be noted by the EEA Joint Committee

To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 July-31 December 2013, at their meeting on 16 May 2014:

| Annex I | List of new marketing authorisations |
| --- | --- |
| Annex II | List of renewed marketing authorisations |
| Annex III | List of extended marketing authorisations |
| Annex IV | List of withdrawn marketing authorisations |
| Annex V | List of suspended marketing authorisations |

Annex I

Annex I

List of new marketing authorisations

Annex II

Annex II

List of renewed marketing authorisations

Annex III

Annex III

List of extended marketing authorisations

Annex IV

Annex IV

List of withdrawn marketing authorisations

Annex V

Annex V

List of suspended marketing authorisations

---

ANNEX I

List of new marketing authorisations

The following marketing authorisations have been granted in the EEA EFTA States during the period 1 July-31 December 2013:

| EU-Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/13/818/001-004 | Bosulif | Liechtenstein | 31.8.2013 |
| EU/1/13/820 | Marixino | Iceland | 22.8.2013 |
| EU/1/13/822 | PHEBURANE | Iceland | 21.8.2013 |
| EU/1/13/822 | PHEBURANE | Norway | 29.8.2013 |
| EU/1/13/830 | Stribild | Norway | 1.7.2013 |
| EU/1/13/831 | Capecitabin SUN | Liechtenstein | 31.8.2013 |
| EU/1/13/831 | Capecitabine SUN | Iceland | 19.7.2013 |
| EU/1/13/831 | Capecitabine SUN | Norway | 26.7.2013 |
| EU/1/13/832 | Stayveer | Liechtenstein | 31.8.2013 |
| EU/1/13/832 | Stayveer | Iceland | 19.7.2013 |
| EU/1/13/832 | Stayveer | Norway | 24.7.2013 |
| EU/1/13/833 | Nuedexta | Liechtenstein | 31.8.2013 |
| EU/1/13/833 | NUEDEXTA | Iceland | 24.7.2013 |
| EU/1/13/833 | Nuedexta | Norway | 3.7.2013 |
| EU/1/13/836 | Memantine ratiopharm | Iceland | 9.8.2013 |
| EU/1/13/838 | AUBAGIO | Liechtenstein | 31.10.2013 |
| EU/1/13/838 | AUBAGIO | Iceland | 9.9.2013 |
| EU/1/13/838 | AUBAGIO | Norway | 18.9.2013 |
| EU/1/13/839 | Iclusig | Liechtenstein | 31.10.2013 |
| EU/1/13/839 | Iclusig | Iceland | 19.7.2013 |
| EU/1/13/839 | Iclusig | Norway | 23.7.2013 |
| EU/1/13/840 | HyQvia | Liechtenstein | 31.10.2013 |
| EU/1/13/841 | Spedra | Liechtenstein | 31.8.2013 |
| EU/1/13/841 | Spedra | Iceland | 19.7.2013 |
| EU/1/13/841 | Spedra | Norway | 19.7.2013 |
| EU/1/13/842 | Incresync | Liechtenstein | 31.10.2013 |
| EU/1/13/842 | Incresync | Iceland | 14.10.2013 |
| EU/1/13/842 | Incresync | Norway | 10.10.2013 |
| EU/1/13/843 | Vipdomet | Liechtenstein | 31.10.2013 |
| EU/1/13/843 | Vipdomet | Iceland | 15.10.2013 |
| EU/1/13/843 | Vipdomet | Norway | 10.10.2013 |
| EU/1/13/844 | Vipidia | Liechtenstein | 31.10.2013 |
| EU/1/13/844 | Vipidia | Iceland | 15.10.2013 |
| EU/1/13/844 | Vipidia | Norway | 10.10.2013 |
| EU/1/13/845 | Imatinib Accord | Iceland | 18.7.2013 |
| EU/1/13/845 | Imatinib Accord | Norway | 18.7.2013 |
| EU/1/13/846 | Xtandi | Iceland | 19.7.2013 |
| EU/1/13/846 | Xtandi | Norway | 17.7.2013 |
| EU/1/13/847 | MACI | Liechtenstein | 31.8.2013 |
| EU/1/13/847 | MACI | Iceland | 24.7.2013 |
| EU/1/13/847 | MACI | Norway | 17.7.2013 |
| EU/1/13/848 | Erivedge | Liechtenstein | 31.8.2013 |
| EU/1/13/848 | Erivedge | Iceland | 8.8.2013 |
| EU/1/13/848 | Erivedge | Norway | 13.8.2013 |
| EU/1/13/849 | Somatropin Biopartners | Liechtenstein | 31.8.2013 |
| EU/1/13/849 | Somatropin Biopartners | Iceland | 22.8.2013 |
| EU/1/13/849 | Somatropin Biopartners | Norway | 10.9.2013 |
| EU/1/13/850 | Pomalidomide Celgene | Iceland | 23.8.2013 |
| EU/1/13/850 | Pomalidomide Celgene | Liechtenstein | 31.10.2013 |
| EU/1/13/850 | Pomalidomide Celgene | Norway | 15.8.2013 |
| EU/1/13/851 | Lojuxta | Liechtenstein | 31.8.2013 |
| EU/1/13/851 | Lojuxta | Iceland | 21.8.2013 |
| EU/1/13/851 | Lojuxta | Norway | 28.8.2013 |
| EU/1/13/852 | Atosiban SUN | Liechtenstein | 31.8.2013 |
| EU/1/13/852 | Atosiban SUN | Iceland | 20.8.2013 |
| EU/1/13/852 | Atosiban SUN | Norway | 29.8.2013 |
| EU/1/13/853 | Remsima | Liechtenstein | 31.10.2013 |
| EU/1/13/853 | Remsima | Iceland | 20.9.2013 |
| EU/1/13/853 | Remsima | Norway | 17.9.2013 |
| EU/1/13/854 | Inflectra | Liechtenstein | 31.10.2013 |
| EU/1/13/854 | Inflectra | Iceland | 20.9.2013 |
| EU/1/13/854 | Inflectra | Norway | 10.10.2013 |
| EU/1/13/855 | Imvanex | Liechtenstein | 31.8.2013 |
| EU/1/13/855 | IMVANEX | Iceland | 23.8.2013 |
| EU/1/13/855 | Imvanex | Norway | 17.9.2013 |
| EU/1/13/856 | Lonquex | Iceland | 20.8.2013 |
| EU/1/13/856 | Lonquex | Norway | 23.8.2013 |
| EU/1/13/857 | Voncento | Liechtenstein | 31.10.2013 |
| EU/1/13/857 | Voncento | Iceland | 11.10.2013 |
| EU/1/13/857 | Voncento | Norway | 16.9.2013 |
| EU/1/13/858 | Stivarga | Liechtenstein | 31.10.2013 |
| EU/1/13/858 | Stivarga | Iceland | 19.9.2013 |
| EU/1/13/858 | Stivarga | Norway | 9.9.2013 |
| EU/1/13/859 | Levodopa/Carbidopa/Entacapone Sandoz | Iceland | 22.11.2013 |
| EU/1/13/859 | Levodopa/Carbidopa/Entacapone Sandoz | Norway | 10.12.2013 |
| EU/1/13/860 | Nexium Control | Liechtenstein | 31.10.2013 |
| EU/1/13/860 | Nexium Control | Iceland | 9.9.2013 |
| EU/1/13/860 | Nexium Control | Norway | 6.9.2013 |
| EU/1/13/861 | Procysbi | Liechtenstein | 31.10.2013 |
| EU/1/13/861 | Procysbi | Iceland | 23.9.2013 |
| EU/1/13/861 | Procysbi | Norway | 24.9.2013 |
| EU/1/13/862 | Ultibro Breezhaler | Liechtenstein | 31.10.2013 |
| EU/1/13/862 | Ultibro Breezhaler | Iceland | 15.10.2013 |
| EU/1/13/862 | Ultibro Breezhaler | Norway | 18.10.2013 |
| EU/1/13/863 | Xoterna Breezhaler | Liechtenstein | 31.10.2013 |
| EU/1/13/863 | Xoterna Breezhaler | Iceland | 14.10.2013 |
| EU/1/13/863 | Xoterna Breezhaler | Norway | 18.10.2013 |
| EU/1/13/865 | Tafinlar | Liechtenstein | 31.10.2013 |
| EU/1/13/865 | Tafinlar | Iceland | 19.9.2013 |
| EU/1/13/865 | Tafinlar | Norway | 18.9.2013 |
| EU/1/13/866 | Cholib | Liechtenstein | 31.10.2013 |
| EU/1/13/866 | Cholib | Iceland | 19.9.2013 |
| EU/1/13/866 | Cholib | Norway | 24.9.2013 |
| EU/1/13/867 | Provenge | Liechtenstein | 31.10.2013 |
| EU/1/13/867 | Provenge | Iceland | 19.9.2013 |
| EU/1/13/867 | Provenge | Norway | 24.9.2013 |
| EU/1/13/868 | EVARREST | Liechtenstein | 31.10.2013 |
| EU/1/13/868 | EVARREST | Iceland | 21.10.2013 |
| EU/1/13/868 | Evarrest | Norway | 18.10.2013 |
| EU/1/13/869 | Lemtrada | Liechtenstein | 31.10.2013 |
| EU/1/13/869 | Lemtrada | Iceland | 23.9.2013 |
| EU/1/13/869 | Lemtrada | Norway | 10.10.2013 |
| EU/1/13/870 | Orphacol | Liechtenstein | 31.10.2013 |
| EU/1/13/870 | Orphacol | Iceland | 10.10.2013 |
| EU/1/13/870 | Orphacol | Norway | 25.9.2013 |
| EU/1/13/871 | Ovaleap | Liechtenstein | 31.10.2013 |
| EU/1/13/871 | Ovaleap | Iceland | 22.10.2013 |
| EU/1/13/871 | Ovaleap | Norway | 17.10.2013 |
| EU/1/13/872 | Tybost | Liechtenstein | 31.10.2013 |
| EU/1/13/872 | Tybost | Iceland | 11.10.2013 |
| EU/1/13/872 | Tybost | Norway | 17.10.2013 |
| EU/1/13/873 | Xofigo | Liechtenstein | 31.12.2013 |
| EU/1/13/873 | Xofigo | Iceland | 11.12.2013 |
| EU/1/13/873 | Xofigo | Norway | 9.12.2013 |
| EU/1/13/876 | Imatinib Medac | Liechtenstein | 31.10.2013 |
| EU/1/13/876 | Imatinib medac | Iceland | 17.10.2013 |
| EU/1/13/876 | Imatinib medac | Norway | 16.10.2013 |
| EU/1/13/877 | Grastofil | Liechtenstein | 31.10.2013 |
| EU/1/13/877 | Grastofil | Iceland | 12.11.2013 |
| EU/1/13/877 | Grastofil | Norway | 18.11.2013 |
| EU/1/13/878 | Defitelio | Liechtenstein | 31.10.2013 |
| EU/1/13/878 | Defitelio | Iceland | 12.11.2013 |
| EU/1/13/878 | Defitelio | Norway | 21.11.2013 |
| EU/1/13/879 | Giotrif | Iceland | 18.10.2013 |
| EU/1/13/879 | Giotrif | Norway | 16.10.2013 |
| EU/1/13/880 | Memantine Accord | Iceland | 16.12.2013 |
| EU/1/13/880 | Memantine Accord | Norway | 17.12.2013 |
| EU/1/13/880 | Memantin Accord | Liechtenstein | 31.12.2013 |
| EU/1/13/881 | Lidocaine/Prilocaine Plethora | Liechtenstein | 31.12.2013 |
| EU/1/13/881 | Lidocaine/Prilocaine Plethora | Iceland | 12.12.2013 |
| EU/1/13/881 | Lidocaine/Prilocaine Plethora | Norway | 16.12.2013 |
| EU/1/13/882 | ABILIFY MAINTENA | Liechtenstein | 31.12.2013 |
| EU/1/13/882 | ABILIFY MAINTENA | Iceland | 12.12.2013 |
| EU/1/13/882 | Abilify Maintena | Norway | 16.12.2013 |
| EU/1/13/883 | Vitekta | Liechtenstein | 31.12.2013 |
| EU/1/13/883 | Vitekta | Iceland | 11.12.2013 |
| EU/1/13/883 | Vitekta | Norway | 16.12.2013 |
| EU/1/13/884 | Invokana | Liechtenstein | 31.12.2013 |
| EU/1/13/884 | Invokana | Iceland | 12.12.2013 |
| EU/1/13/884 | Invokana | Norway | 16.12.2013 |
| EU/1/13/885 | Kadcyla | Liechtenstein | 31.12.2013 |
| EU/1/13/885 | Kadcyla | Iceland | 12.12.2013 |
| EU/1/13/885 | Kadcyla | Norway | 16.12.2013 |
| EU/1/13/886 | Relvar Ellipta | Iceland | 11.12.2013 |
| EU/1/13/886 | Relvar Ellipta | Liechtenstein | 31.12.2013 |
| EU/1/13/886 | Relvar Ellipta | Norway | 25.11.2013 |
| EU/1/13/887 | Fluenz Tetra | Norway | 4.12.2013 |
| EU/1/13/888 | NovoEight | Liechtenstein | 31.12.2013 |
| EU/1/13/888 | NovoEight | Iceland | 11.12.2013 |
| EU/1/13/888 | NovoEight | Norway | 16.12.2013 |
| EU/1/13/893 | Opsumit | Norway | 20.12.2013 |
| EU/2/13/148 | Meloxidolor | Norway | 6.8.2013 |
| EU/2/13/150 | Oncept IL-2 | Iceland | 18.7.2013 |
| EU/2/13/152 | ProZinc | Iceland | 8.8.2013 |
| EU/2/13/152 | ProZinc | Norway | 5.8.2013 |
| EU/2/13/153 | Aftovaxpur Doe | Liechtenstein | 31.8.2013 |
| EU/2/13/153 | Aftovaxpur Doe | Iceland | 9.8.2013 |
| EU/2/13/153 | Aftovaxpur Doe | Norway | 15.7.2013 |
| EU/2/13/154 | Apoquel | Liechtenstein | 31.10.2013 |
| EU/2/13/154 | Apoquel | Iceland | 20.9.2013 |
| EU/2/13/154 | Apoquel | Norway | 12.9.2013 |
| EU/2/13/155 | Trifexis | Liechtenstein | 31.10.2013 |
| EU/2/13/155 | Trifexis | Iceland | 14.10.2013 |
| EU/2/13/156 | Vectra 3D | Liechtenstein | 31.12.2013 |
| EU/2/13/156 | Vectra 3D | Iceland | 23.12.2013 |
| EU/2/13/157 | BROADLINE | Liechtenstein | 31.12.2013 |
| EU/2/13/157 | BROADLINE | Iceland | 23.12.2013 |

EU-Number

Product

Country

Date of authorisation

EU/1/13/818/001-004

Bosulif

Liechtenstein

31.8.2013

EU/1/13/820

Marixino

Iceland

22.8.2013

EU/1/13/822

PHEBURANE

Iceland

21.8.2013

EU/1/13/822

PHEBURANE

Norway

29.8.2013

EU/1/13/830

Stribild

Norway

1.7.2013

EU/1/13/831

Capecitabin SUN

Liechtenstein

31.8.2013

EU/1/13/831

Capecitabine SUN

Iceland

19.7.2013

EU/1/13/831

Capecitabine SUN

Norway

26.7.2013

EU/1/13/832

Stayveer

Liechtenstein

31.8.2013

EU/1/13/832

Stayveer

Iceland

19.7.2013

EU/1/13/832

Stayveer

Norway

24.7.2013

EU/1/13/833

Nuedexta

Liechtenstein

31.8.2013

EU/1/13/833

NUEDEXTA

Iceland

24.7.2013

EU/1/13/833

Nuedexta

Norway

3.7.2013

EU/1/13/836

Memantine ratiopharm

Iceland

9.8.2013

EU/1/13/838

AUBAGIO

Liechtenstein

31.10.2013

EU/1/13/838

AUBAGIO

Iceland

9.9.2013

EU/1/13/838

AUBAGIO

Norway

18.9.2013

EU/1/13/839

Iclusig

Liechtenstein

31.10.2013

EU/1/13/839

Iclusig

Iceland

19.7.2013

EU/1/13/839

Iclusig

Norway

23.7.2013

EU/1/13/840

HyQvia

Liechtenstein

31.10.2013

EU/1/13/841

Spedra

Liechtenstein

31.8.2013

EU/1/13/841

Spedra

Iceland

19.7.2013

EU/1/13/841

Spedra

Norway

19.7.2013

EU/1/13/842

Incresync

Liechtenstein

31.10.2013

EU/1/13/842

Incresync

Iceland

14.10.2013

EU/1/13/842

Incresync

Norway

10.10.2013

EU/1/13/843

Vipdomet

Liechtenstein

31.10.2013

EU/1/13/843

Vipdomet

Iceland

15.10.2013

EU/1/13/843

Vipdomet

Norway

10.10.2013

EU/1/13/844

Vipidia

Liechtenstein

31.10.2013

EU/1/13/844

Vipidia

Iceland

15.10.2013

EU/1/13/844

Vipidia

Norway

10.10.2013

EU/1/13/845

Imatinib Accord

Iceland

18.7.2013

EU/1/13/845

Imatinib Accord

Norway

18.7.2013

EU/1/13/846

Xtandi

Iceland

19.7.2013

EU/1/13/846

Xtandi

Norway

17.7.2013

EU/1/13/847

MACI

Liechtenstein

31.8.2013

EU/1/13/847

MACI

Iceland

24.7.2013

EU/1/13/847

MACI

Norway

17.7.2013

EU/1/13/848

Erivedge

Liechtenstein

31.8.2013

EU/1/13/848

Erivedge

Iceland

8.8.2013

EU/1/13/848

Erivedge

Norway

13.8.2013

EU/1/13/849

Somatropin Biopartners

Liechtenstein

31.8.2013

EU/1/13/849

Somatropin Biopartners

Iceland

22.8.2013

EU/1/13/849

Somatropin Biopartners

Norway

10.9.2013

EU/1/13/850

Pomalidomide Celgene

Iceland

23.8.2013

EU/1/13/850

Pomalidomide Celgene

Liechtenstein

31.10.2013

EU/1/13/850

Pomalidomide Celgene

Norway

15.8.2013

EU/1/13/851

Lojuxta

Liechtenstein

31.8.2013

EU/1/13/851

Lojuxta

Iceland

21.8.2013

EU/1/13/851

Lojuxta

Norway

28.8.2013

EU/1/13/852

Atosiban SUN

Liechtenstein

31.8.2013

EU/1/13/852

Atosiban SUN

Iceland

20.8.2013

EU/1/13/852

Atosiban SUN

Norway

29.8.2013

EU/1/13/853

Remsima

Liechtenstein

31.10.2013

EU/1/13/853

Remsima

Iceland

20.9.2013

EU/1/13/853

Remsima

Norway

17.9.2013

EU/1/13/854

Inflectra

Liechtenstein

31.10.2013

EU/1/13/854

Inflectra

Iceland

20.9.2013

EU/1/13/854

Inflectra

Norway

10.10.2013

EU/1/13/855

Imvanex

Liechtenstein

31.8.2013

EU/1/13/855

IMVANEX

Iceland

23.8.2013

EU/1/13/855

Imvanex

Norway

17.9.2013

EU/1/13/856

Lonquex

Iceland

20.8.2013

EU/1/13/856

Lonquex

Norway

23.8.2013

EU/1/13/857

Voncento

Liechtenstein

31.10.2013

EU/1/13/857

Voncento

Iceland

11.10.2013

EU/1/13/857

Voncento

Norway

16.9.2013

EU/1/13/858

Stivarga

Liechtenstein

31.10.2013

EU/1/13/858

Stivarga

Iceland

19.9.2013

EU/1/13/858

Stivarga

Norway

9.9.2013

EU/1/13/859

Levodopa/Carbidopa/Entacapone Sandoz

Iceland

22.11.2013

EU/1/13/859

Levodopa/Carbidopa/Entacapone Sandoz

Norway

10.12.2013

EU/1/13/860

Nexium Control

Liechtenstein

31.10.2013

EU/1/13/860

Nexium Control

Iceland

9.9.2013

EU/1/13/860

Nexium Control

Norway

6.9.2013

EU/1/13/861

Procysbi

Liechtenstein

31.10.2013

EU/1/13/861

Procysbi

Iceland

23.9.2013

EU/1/13/861

Procysbi

Norway

24.9.2013

EU/1/13/862

Ultibro Breezhaler

Liechtenstein

31.10.2013

EU/1/13/862

Ultibro Breezhaler

Iceland

15.10.2013

EU/1/13/862

Ultibro Breezhaler

Norway

18.10.2013

EU/1/13/863

Xoterna Breezhaler

Liechtenstein

31.10.2013

EU/1/13/863

Xoterna Breezhaler

Iceland

14.10.2013

EU/1/13/863

Xoterna Breezhaler

Norway

18.10.2013

EU/1/13/865

Tafinlar

Liechtenstein

31.10.2013

EU/1/13/865

Tafinlar

Iceland

19.9.2013

EU/1/13/865

Tafinlar

Norway

18.9.2013

EU/1/13/866

Cholib

Liechtenstein

31.10.2013

EU/1/13/866

Cholib

Iceland

19.9.2013

EU/1/13/866

Cholib

Norway

24.9.2013

EU/1/13/867

Provenge

Liechtenstein

31.10.2013

EU/1/13/867

Provenge

Iceland

19.9.2013

EU/1/13/867

Provenge

Norway

24.9.2013

EU/1/13/868

EVARREST

Liechtenstein

31.10.2013

EU/1/13/868

EVARREST

Iceland

21.10.2013

EU/1/13/868

Evarrest

Norway

18.10.2013

EU/1/13/869

Lemtrada

Liechtenstein

31.10.2013

EU/1/13/869

Lemtrada

Iceland

23.9.2013

EU/1/13/869

Lemtrada

Norway

10.10.2013

EU/1/13/870

Orphacol

Liechtenstein

31.10.2013

EU/1/13/870

Orphacol

Iceland

10.10.2013

EU/1/13/870

Orphacol

Norway

25.9.2013

EU/1/13/871

Ovaleap

Liechtenstein

31.10.2013

EU/1/13/871

Ovaleap

Iceland

22.10.2013

EU/1/13/871

Ovaleap

Norway

17.10.2013

EU/1/13/872

Tybost

Liechtenstein

31.10.2013

EU/1/13/872

Tybost

Iceland

11.10.2013

EU/1/13/872

Tybost

Norway

17.10.2013

EU/1/13/873

Xofigo

Liechtenstein

31.12.2013

EU/1/13/873

Xofigo

Iceland

11.12.2013

EU/1/13/873

Xofigo

Norway

9.12.2013

EU/1/13/876

Imatinib Medac

Liechtenstein

31.10.2013

EU/1/13/876

Imatinib medac

Iceland

17.10.2013

EU/1/13/876

Imatinib medac

Norway

16.10.2013

EU/1/13/877

Grastofil

Liechtenstein

31.10.2013

EU/1/13/877

Grastofil

Iceland

12.11.2013

EU/1/13/877

Grastofil

Norway

18.11.2013

EU/1/13/878

Defitelio

Liechtenstein

31.10.2013

EU/1/13/878

Defitelio

Iceland

12.11.2013

EU/1/13/878

Defitelio

Norway

21.11.2013

EU/1/13/879

Giotrif

Iceland

18.10.2013

EU/1/13/879

Giotrif

Norway

16.10.2013

EU/1/13/880

Memantine Accord

Iceland

16.12.2013

EU/1/13/880

Memantine Accord

Norway

17.12.2013

EU/1/13/880

Memantin Accord

Liechtenstein

31.12.2013

EU/1/13/881

Lidocaine/Prilocaine Plethora

Liechtenstein

31.12.2013

EU/1/13/881

Lidocaine/Prilocaine Plethora

Iceland

12.12.2013

EU/1/13/881

Lidocaine/Prilocaine Plethora

Norway

16.12.2013

EU/1/13/882

ABILIFY MAINTENA

Liechtenstein

31.12.2013

EU/1/13/882

ABILIFY MAINTENA

Iceland

12.12.2013

EU/1/13/882

Abilify Maintena

Norway

16.12.2013

EU/1/13/883

Vitekta

Liechtenstein

31.12.2013

EU/1/13/883

Vitekta

Iceland

11.12.2013

EU/1/13/883

Vitekta

Norway

16.12.2013

EU/1/13/884

Invokana

Liechtenstein

31.12.2013

EU/1/13/884

Invokana

Iceland

12.12.2013

EU/1/13/884

Invokana

Norway

16.12.2013

EU/1/13/885

Kadcyla

Liechtenstein

31.12.2013

EU/1/13/885

Kadcyla

Iceland

12.12.2013

EU/1/13/885

Kadcyla

Norway

16.12.2013

EU/1/13/886

Relvar Ellipta

Iceland

11.12.2013

EU/1/13/886

Relvar Ellipta

Liechtenstein

31.12.2013

EU/1/13/886

Relvar Ellipta

Norway

25.11.2013

EU/1/13/887

Fluenz Tetra

Norway

4.12.2013

EU/1/13/888

NovoEight

Liechtenstein

31.12.2013

EU/1/13/888

NovoEight

Iceland

11.12.2013

EU/1/13/888

NovoEight

Norway

16.12.2013

EU/1/13/893

Opsumit

Norway

20.12.2013

EU/2/13/148

Meloxidolor

Norway

6.8.2013

EU/2/13/150

Oncept IL-2

Iceland

18.7.2013

EU/2/13/152

ProZinc

Iceland

8.8.2013

EU/2/13/152

ProZinc

Norway

5.8.2013

EU/2/13/153

Aftovaxpur Doe

Liechtenstein

31.8.2013

EU/2/13/153

Aftovaxpur Doe

Iceland

9.8.2013

EU/2/13/153

Aftovaxpur Doe

Norway

15.7.2013

EU/2/13/154

Apoquel

Liechtenstein

31.10.2013

EU/2/13/154

Apoquel

Iceland

20.9.2013

EU/2/13/154

Apoquel

Norway

12.9.2013

EU/2/13/155

Trifexis

Liechtenstein

31.10.2013

EU/2/13/155

Trifexis

Iceland

14.10.2013

EU/2/13/156

Vectra 3D

Liechtenstein

31.12.2013

EU/2/13/156

Vectra 3D

Iceland

23.12.2013

EU/2/13/157

BROADLINE

Liechtenstein

31.12.2013

EU/2/13/157

BROADLINE

Iceland

23.12.2013

---

ANNEX II

List of renewed marketing authorisations

The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 July-31 December 2013:

| EU-Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/03/255 | Ventavis | Liechtenstein | 31.10.2013 |
| EU/1/03/255 | Ventavis | Iceland | 9.9.2013 |
| EU/1/03/255 | Ventavis | Norway | 18.9.2013 |
| EU/1/06/380 | Prezista | Iceland | 11.10.2013 |
| EU/1/06/380 | Prezista | Norway | 18.10.2013 |
| EU/1/07/440 | Tyverb | Iceland | 26.8.2013 |
| EU/1/08/444 | Ratiograstim | Liechtenstein | 31.8.2013 |
| EU/1/08/444 | Ratiograstim | Iceland | 19.8.2013 |
| EU/1/08/444 | Ratiograstim | Norway | 15.8.2013 |
| EU/1/08/445 | Tevagrastim | Liechtenstein | 31.8.2013 |
| EU/1/08/445 | Tevagrastim | Iceland | 19.8.2013 |
| EU/1/08/445 | Tevagrastim | Norway | 15.8.2013 |
| EU/1/08/450 | Biograstim | Liechtenstein | 31.8.2013 |
| EU/1/08/450 | Biograstim | Iceland | 20.8.2013 |
| EU/1/08/450 | Biograstim | Norway | 27.8.2013 |
| EU/1/08/456 | Velmetia | Norway | 11.9.2013 |
| EU/1/08/457 | Efficib | Norway | 11.9.2013 |
| EU/1/08/466 | Bridion | Liechtenstein | 31.8.2013 |
| EU/1/08/466 | Bridion | Iceland | 17.7.2013 |
| EU/1/08/466 | Bridion | Norway | 19.7.2013 |
| EU/1/08/467 | Doribax | Norway | 29.7.2013 |
| EU/1/08/468 | INTELENCE | Iceland | 17.7.2013 |
| EU/1/08/468 | Intelence | Norway | 24.7.2013 |
| EU/1/08/470 | Vimpat | Liechtenstein | 31.8.2013 |
| EU/1/08/470 | Vimpat | Iceland | 21.8.2013 |
| EU/1/08/470 | Vimpat | Norway | 13.8.2013 |
| EU/1/08/473 | Evicel | Liechtenstein | 31.12.2013 |
| EU/1/08/473 | Evicel | Iceland | 16.12.2013 |
| EU/1/08/473 | Evicel | Norway | 18.12.2013 |
| EU/1/08/477 | Ceplene | Liechtenstein | 31.10.2013 |
| EU/1/08/477 | Ceplene | Iceland | 11.9.2013 |
| EU/1/08/477 | Ceplene | Norway | 18.9.2013 |
| EU/1/08/479 | Zypadhera | Iceland | 9.9.2013 |
| EU/1/08/479 | Zypadhera | Norway | 9.9.2013 |
| EU/1/08/480 | Ifirmasta | Liechtenstein | 31.8.2013 |
| EU/1/08/480 | Ifirmasta | Iceland | 9.9.2013 |
| EU/1/08/480 | Ifirmasta | Norway | 11.9.2013 |
| EU/1/08/481 | Kuvan | Liechtenstein | 31.12.2013 |
| EU/1/08/481 | Kuvan | Iceland | 11.12.2013 |
| EU/1/08/481 | Kuvan | Norway | 10.12.2013 |
| EU/1/08/482 | Azarga | Iceland | 5.9.2013 |
| EU/1/08/482 | Azarga | Norway | 18.9.2013 |
| EU/1/08/483 | Zomarist | Iceland | 21.8.2013 |
| EU/1/08/483 | Zomarist | Norway | 5.9.2013 |
| EU/1/08/484 | Icandra | Iceland | 21.8.2013 |
| EU/1/08/484 | Icandra | Norway | 5.9.2013 |
| EU/1/08/485 | Jalra | Liechtenstein | 31.12.2013 |
| EU/1/08/485 | Jalra | Iceland | 16.12.2013 |
| EU/1/08/485 | Jalra | Norway | 16.12.2013 |
| EU/1/08/486 | Xiliarx | Liechtenstein | 31.12.2013 |
| EU/1/08/486 | Xiliarx | Iceland | 16.12.2013 |
| EU/1/08/486 | Xiliarx | Norway | 16.12.2013 |
| EU/1/08/488 | Vidaza | Liechtenstein | 31.12.2013 |
| EU/1/08/488 | Vidaza | Iceland | 10.12.2013 |
| EU/1/08/488 | Vidaza | Norway | 16.12.2013 |
| EU/1/08/489 | Opgenra | Liechtenstein | 31.12.2013 |
| EU/1/08/489 | Opgenra | Iceland | 16.12.2013 |
| EU/1/08/489 | Opgenra | Norway | 16.12.2013 |
| EU/1/08/490 | Pramipexole Teva | Iceland | 23.9.2013 |
| EU/1/08/490 | Pramipexole Teva | Norway | 20.9.2013 |
| EU/1/08/491 | Rasilez HCT | Liechtenstein | 31.12.2013 |
| EU/1/08/491 | Rasilez HCT | Iceland | 25.11.2013 |
| EU/1/08/491 | Rasilez HCT | Norway | 18.12.2013 |
| EU/1/08/492 | RoActemra | Iceland | 17.10.2013 |
| EU/1/08/492 | RoActemra | Norway | 16.10.2013 |
| EU/1/08/494 | Stelara | Liechtenstein | 31.10.2013 |
| EU/1/08/494 | Stelara | Iceland | 14.10.2013 |
| EU/1/08/494 | Stelara | Norway | 2.10.2013 |
| EU/1/08/495 | Zarzio | Liechtenstein | 31.12.2013 |
| EU/1/08/495 | Zarzio | Iceland | 26.11.2013 |
| EU/1/08/495 | Zarzio | Norway | 16.12.2013 |
| EU/1/08/496 | Filgrastim Hexal | Liechtenstein | 31.12.2013 |
| EU/1/08/496 | Filgrastim Hexal | Iceland | 25.11.2013 |
| EU/1/08/496 | Filgrastim Hexal | Norway | 16.12.2013 |
| EU/1/08/498 | Thymanax | Liechtenstein | 31.12.2013 |
| EU/1/08/498 | Thymanax | Iceland | 25.11.2013 |
| EU/1/08/498 | Thymanax | Norway | 16.12.2013 |
| EU/1/08/499 | Valdoxan | Iceland | 25.11.2013 |
| EU/1/08/499 | Valdoxan | Norway | 17.12.2013 |
| EU/1/08/503 | Efient | Liechtenstein | 31.12.2013 |
| EU/1/08/503 | Efient | Iceland | 10.12.2013 |
| EU/1/08/503 | Efient | Norway | 18.12.2013 |
| EU/1/08/504 | Firmagon | Iceland | 10.12.2013 |
| EU/1/08/504 | Firmagon | Norway | 16.12.2013 |
| EU/1/08/505 | Intanza | Iceland | 17.10.2013 |
| EU/1/08/505 | Intanza | Norway | 22.10.2013 |
| EU/1/08/507 | IDflu | Iceland | 17.10.2013 |
| EU/1/08/507 | IDflu | Norway | 22.10.2013 |
| EU/1/10/628 | Votrient | Iceland | 1.8.2013 |
| EU/1/10/628 | Votrient | Norway | 13.8.2013 |
| EU/1/11/699 | Fampyra | Iceland | 17.7.2013 |
| EU/1/11/699 | Fampyra | Norway | 12.8.2013 |
| EU/1/11/710 | Votubia | Liechtenstein | 31.8.2013 |
| EU/1/11/710 | Votubia | Iceland | 9.8.2013 |
| EU/1/11/710 | Votubia | Norway | 13.8.2013 |
| EU/1/12/793 | Xalkori | Iceland | 10.9.2013 |
| EU/1/12/793 | Xalkori | Norway | 26.8.2013 |
| EU/1/12/794 | Adcetris | Iceland | 9.9.2013 |
| EU/1/12/794 | Adcetris | Norway | 23.9.2013 |
| EU/1/99/103 | ReFacto AF | Liechtenstein | 31.12.2013 |
| EU/1/99/103 | Refacto AF | Norway | 18.12.2013 |
| EU/2/07/075 | Circovac | Norway | 9.8.2013 |
| EU/2/08/080 | Reconcile | Liechtenstein | 31.8.2013 |
| EU/2/08/080 | Reconcile | Iceland | 8.8.2013 |
| EU/2/08/082 | Zactran | Liechtenstein | 31.8.2013 |
| EU/2/08/082 | Zactran | Iceland | 9.8.2013 |
| EU/2/08/082 | Zactran | Norway | 12.8.2013 |
| EU/2/08/084 | Trocoxil | Iceland | 4.9.2013 |
| EU/2/08/086 | Equip WNV | Liechtenstein | 31.10.2013 |
| EU/2/08/086 | Equip WNV | Iceland | 24.9.2013 |
| EU/2/08/087 | Masivet | Liechtenstein | 31.10.2013 |
| EU/2/08/087 | Masivet | Iceland | 17.10.2013 |
| EU/2/08/089 | Onsior | Iceland | 22.11.2013 |
| EU/2/08/091 | Porcilis PCV | Liechtenstein | 31.12.2013 |

EU-Number

Product

Country

Date of authorisation

EU/1/03/255

Ventavis

Liechtenstein

31.10.2013

EU/1/03/255

Ventavis

Iceland

9.9.2013

EU/1/03/255

Ventavis

Norway

18.9.2013

EU/1/06/380

Prezista

Iceland

11.10.2013

EU/1/06/380

Prezista

Norway

18.10.2013

EU/1/07/440

Tyverb

Iceland

26.8.2013

EU/1/08/444

Ratiograstim

Liechtenstein

31.8.2013

EU/1/08/444

Ratiograstim

Iceland

19.8.2013

EU/1/08/444

Ratiograstim

Norway

15.8.2013

EU/1/08/445

Tevagrastim

Liechtenstein

31.8.2013

EU/1/08/445

Tevagrastim

Iceland

19.8.2013

EU/1/08/445

Tevagrastim

Norway

15.8.2013

EU/1/08/450

Biograstim

Liechtenstein

31.8.2013

EU/1/08/450

Biograstim

Iceland

20.8.2013

EU/1/08/450

Biograstim

Norway

27.8.2013

EU/1/08/456

Velmetia

Norway

11.9.2013

EU/1/08/457

Efficib

Norway

11.9.2013

EU/1/08/466

Bridion

Liechtenstein

31.8.2013

EU/1/08/466

Bridion

Iceland

17.7.2013

EU/1/08/466

Bridion

Norway

19.7.2013

EU/1/08/467

Doribax

Norway

29.7.2013

EU/1/08/468

INTELENCE

Iceland

17.7.2013

EU/1/08/468

Intelence

Norway

24.7.2013

EU/1/08/470

Vimpat

Liechtenstein

31.8.2013

EU/1/08/470

Vimpat

Iceland

21.8.2013

EU/1/08/470

Vimpat

Norway

13.8.2013

EU/1/08/473

Evicel

Liechtenstein

31.12.2013

EU/1/08/473

Evicel

Iceland

16.12.2013

EU/1/08/473

Evicel

Norway

18.12.2013

EU/1/08/477

Ceplene

Liechtenstein

31.10.2013

EU/1/08/477

Ceplene

Iceland

11.9.2013

EU/1/08/477

Ceplene

Norway

18.9.2013

EU/1/08/479

Zypadhera

Iceland

9.9.2013

EU/1/08/479

Zypadhera

Norway

9.9.2013

EU/1/08/480

Ifirmasta

Liechtenstein

31.8.2013

EU/1/08/480

Ifirmasta

Iceland

9.9.2013

EU/1/08/480

Ifirmasta

Norway

11.9.2013

EU/1/08/481

Kuvan

Liechtenstein

31.12.2013

EU/1/08/481

Kuvan

Iceland

11.12.2013

EU/1/08/481

Kuvan

Norway

10.12.2013

EU/1/08/482

Azarga

Iceland

5.9.2013

EU/1/08/482

Azarga

Norway

18.9.2013

EU/1/08/483

Zomarist

Iceland

21.8.2013

EU/1/08/483

Zomarist

Norway

5.9.2013

EU/1/08/484

Icandra

Iceland

21.8.2013

EU/1/08/484

Icandra

Norway

5.9.2013

EU/1/08/485

Jalra

Liechtenstein

31.12.2013

EU/1/08/485

Jalra

Iceland

16.12.2013

EU/1/08/485

Jalra

Norway

16.12.2013

EU/1/08/486

Xiliarx

Liechtenstein

31.12.2013

EU/1/08/486

Xiliarx

Iceland

16.12.2013

EU/1/08/486

Xiliarx

Norway

16.12.2013

EU/1/08/488

Vidaza

Liechtenstein

31.12.2013

EU/1/08/488

Vidaza

Iceland

10.12.2013

EU/1/08/488

Vidaza

Norway

16.12.2013

EU/1/08/489

Opgenra

Liechtenstein

31.12.2013

EU/1/08/489

Opgenra

Iceland

16.12.2013

EU/1/08/489

Opgenra

Norway

16.12.2013

EU/1/08/490

Pramipexole Teva

Iceland

23.9.2013

EU/1/08/490

Pramipexole Teva

Norway

20.9.2013

EU/1/08/491

Rasilez HCT

Liechtenstein

31.12.2013

EU/1/08/491

Rasilez HCT

Iceland

25.11.2013

EU/1/08/491

Rasilez HCT

Norway

18.12.2013

EU/1/08/492

RoActemra

Iceland

17.10.2013

EU/1/08/492

RoActemra

Norway

16.10.2013

EU/1/08/494

Stelara

Liechtenstein

31.10.2013

EU/1/08/494

Stelara

Iceland

14.10.2013

EU/1/08/494

Stelara

Norway

2.10.2013

EU/1/08/495

Zarzio

Liechtenstein

31.12.2013

EU/1/08/495

Zarzio

Iceland

26.11.2013

EU/1/08/495

Zarzio

Norway

16.12.2013

EU/1/08/496

Filgrastim Hexal

Liechtenstein

31.12.2013

EU/1/08/496

Filgrastim Hexal

Iceland

25.11.2013

EU/1/08/496

Filgrastim Hexal

Norway

16.12.2013

EU/1/08/498

Thymanax

Liechtenstein

31.12.2013

EU/1/08/498

Thymanax

Iceland

25.11.2013

EU/1/08/498

Thymanax

Norway

16.12.2013

EU/1/08/499

Valdoxan

Iceland

25.11.2013

EU/1/08/499

Valdoxan

Norway

17.12.2013

EU/1/08/503

Efient

Liechtenstein

31.12.2013

EU/1/08/503

Efient

Iceland

10.12.2013

EU/1/08/503

Efient

Norway

18.12.2013

EU/1/08/504

Firmagon

Iceland

10.12.2013

EU/1/08/504

Firmagon

Norway

16.12.2013

EU/1/08/505

Intanza

Iceland

17.10.2013

EU/1/08/505

Intanza

Norway

22.10.2013

EU/1/08/507

IDflu

Iceland

17.10.2013

EU/1/08/507

IDflu

Norway

22.10.2013

EU/1/10/628

Votrient

Iceland

1.8.2013

EU/1/10/628

Votrient

Norway

13.8.2013

EU/1/11/699

Fampyra

Iceland

17.7.2013

EU/1/11/699

Fampyra

Norway

12.8.2013

EU/1/11/710

Votubia

Liechtenstein

31.8.2013

EU/1/11/710

Votubia

Iceland

9.8.2013

EU/1/11/710

Votubia

Norway

13.8.2013

EU/1/12/793

Xalkori

Iceland

10.9.2013

EU/1/12/793

Xalkori

Norway

26.8.2013

EU/1/12/794

Adcetris

Iceland

9.9.2013

EU/1/12/794

Adcetris

Norway

23.9.2013

EU/1/99/103

ReFacto AF

Liechtenstein

31.12.2013

EU/1/99/103

Refacto AF

Norway

18.12.2013

EU/2/07/075

Circovac

Norway

9.8.2013

EU/2/08/080

Reconcile

Liechtenstein

31.8.2013

EU/2/08/080

Reconcile

Iceland

8.8.2013

EU/2/08/082

Zactran

Liechtenstein

31.8.2013

EU/2/08/082

Zactran

Iceland

9.8.2013

EU/2/08/082

Zactran

Norway

12.8.2013

EU/2/08/084

Trocoxil

Iceland

4.9.2013

EU/2/08/086

Equip WNV

Liechtenstein

31.10.2013

EU/2/08/086

Equip WNV

Iceland

24.9.2013

EU/2/08/087

Masivet

Liechtenstein

31.10.2013

EU/2/08/087

Masivet

Iceland

17.10.2013

EU/2/08/089

Onsior

Iceland

22.11.2013

EU/2/08/091

Porcilis PCV

Liechtenstein

31.12.2013

---

ANNEX III

List of extended marketing authorisations

The following marketing authorisations have been extended in the EEA EFTA States during the period 1 July-31 December 2013:

| EU-Number | Product | Country | Date of authorisation |
| --- | --- | --- | --- |
| EU/1/00/145/002 | Herceptin | Norway | 6.9.2013 |
| EU/1/00/145/002 | Herceptin | Iceland | 9.9.2013 |
| EU/1/02/203/005-007 | Kineret | Norway | 13.12.2013 |
| EU/1/02/203/005-007 | Kineret | Iceland | 13.12.2013 |
| EU/1/03/249/016 | Vivanza | Norway | 5.8.2013 |
| EU/1/03/249/016 | Vivanza | Iceland | 17.7.2013 |
| EU/1/07/436/003-004 | Isentress | Norway | 4.7.2013 |
| EU/1/08/469/026-045 | Oprymea | Norway | 25.11.2013 |
| EU/1/08/469/026-045 | Oprymea | Iceland | 22.11.2013 |
| EU/1/09/546/005-008 | Simponi | Norway | 7.10.2013 |
| EU/1/09/546/005-008 | Simponi | Iceland | 12.9.2013 |
| EU/1/10/612/007-009 | Revolade | Norway | 10.10.2013 |
| EU/1/10/612/007-009 | Revolade | Iceland | 11.10.2013 |
| EU/1/10/637/010-013 | Leflunomide medac | Norway | 27.8.2013 |
| EU/1/10/637/010-013 | Leflunomide medac | Iceland | 19.8.2013 |
| EU/1/11/706/034-038 | Levodopa/Carbidopa/Entacapone Orion | Norway | 18.10.2013 |
| EU/1/11/706/034-038 | Levodopa/Carbidopa/Entacapone Orion | Iceland | 18.7.2013 |
| EU/1/11/710/009-015 | Votubia | Norway | 13.12.2013 |
| EU/1/12/777/007-012 | Inlyta | Norway | 18.9.2013 |
| EU/1/12/777/007-012 | Inlyta | Iceland | 4.9.2013 |
| EU/1/97/030/202-203 | Insuman Implantable | Norway | 18.10.2013 |
| EU/2/04/044/015-016 | Aivlosin | Iceland | 23.12.2013 |
| EU/2/08/090/029-031 | Loxicom | Norway | 26.9.2013 |
| EU/2/09/098/002-007 | Melovem | Iceland | 21.10.2013 |
| EU/2/10/115/011-019 | Comfortis | Norway | 6.8.2013 |
| EU/2/10/115/020-021 | Comfortis | Iceland | 11.12.2013 |

EU-Number

Product

Country

Date of authorisation

EU/1/00/145/002

Herceptin

Norway

6.9.2013

EU/1/00/145/002

Herceptin

Iceland

9.9.2013

EU/1/02/203/005-007

Kineret

Norway

13.12.2013

EU/1/02/203/005-007

Kineret

Iceland

13.12.2013

EU/1/03/249/016

Vivanza

Norway

5.8.2013

EU/1/03/249/016

Vivanza

Iceland

17.7.2013

EU/1/07/436/003-004

Isentress

Norway

4.7.2013

EU/1/08/469/026-045

Oprymea

Norway

25.11.2013

EU/1/08/469/026-045

Oprymea

Iceland

22.11.2013

EU/1/09/546/005-008

Simponi

Norway

7.10.2013

EU/1/09/546/005-008

Simponi

Iceland

12.9.2013

EU/1/10/612/007-009

Revolade

Norway

10.10.2013

EU/1/10/612/007-009

Revolade

Iceland

11.10.2013

EU/1/10/637/010-013

Leflunomide medac

Norway

27.8.2013

EU/1/10/637/010-013

Leflunomide medac

Iceland

19.8.2013

EU/1/11/706/034-038

Levodopa/Carbidopa/Entacapone Orion

Norway

18.10.2013

EU/1/11/706/034-038

Levodopa/Carbidopa/Entacapone Orion

Iceland

18.7.2013

EU/1/11/710/009-015

Votubia

Norway

13.12.2013

EU/1/12/777/007-012

Inlyta

Norway

18.9.2013

EU/1/12/777/007-012

Inlyta

Iceland

4.9.2013

EU/1/97/030/202-203

Insuman Implantable

Norway

18.10.2013

EU/2/04/044/015-016

Aivlosin

Iceland

23.12.2013

EU/2/08/090/029-031

Loxicom

Norway

26.9.2013

EU/2/09/098/002-007

Melovem

Iceland

21.10.2013

EU/2/10/115/011-019

Comfortis

Norway

6.8.2013

EU/2/10/115/020-021

Comfortis

Iceland

11.12.2013

---

ANNEX IV

List of withdrawn marketing authorisations

The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 July-31 December 2013:

| EU-Number | Product | Country | Date of withdrawal |
| --- | --- | --- | --- |
| EU/1/01/189 | Replagal | Norway | 14.8.2013 |
| EU/1/03/266 | Bondenza | Iceland | 12.11.2013 |
| EU/1/09/554 | Clopidogrel ratiopharm | Norway | 25.11.2013 |
| EU/1/10/656 | Possia | Liechtenstein | 31.8.2013 |
| EU/1/11/687 | Hizentra | Norway | 14.8.2013 |
| EU/1/11/730 | Rasitrio | Iceland | 20.9.2013 |
| EU/1/11/730 | Rasitrio | Norway | 3.9.2013 |
| EU/1/12/754 | Sepioglin | Iceland | 12.11.2013 |
| EU/2/00/022 | Ibaflin | Liechtenstein | 31.8.2013 |
| EU/2/09/093 | Netvax | Liechtenstein | 31.10.2013 |
| EU/2/09/093 | Netvax | Iceland | 16.10.2013 |
| EU/2/09/093 | Netvax | Norway | 19.9.2013 |
| EU/2/98/010 | Econor | Norway | 5.8.2013 |

EU-Number

Product

Country

Date of withdrawal

EU/1/01/189

Replagal

Norway

14.8.2013

EU/1/03/266

Bondenza

Iceland

12.11.2013

EU/1/09/554

Clopidogrel ratiopharm

Norway

25.11.2013

EU/1/10/656

Possia

Liechtenstein

31.8.2013

EU/1/11/687

Hizentra

Norway

14.8.2013

EU/1/11/730

Rasitrio

Iceland

20.9.2013

EU/1/11/730

Rasitrio

Norway

3.9.2013

EU/1/12/754

Sepioglin

Iceland

12.11.2013

EU/2/00/022

Ibaflin

Liechtenstein

31.8.2013

EU/2/09/093

Netvax

Liechtenstein

31.10.2013

EU/2/09/093

Netvax

Iceland

16.10.2013

EU/2/09/093

Netvax

Norway

19.9.2013

EU/2/98/010

Econor

Norway

5.8.2013

---

ANNEX V

List of suspended marketing authorisations

The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 July-31 December 2013:

| EU-Number | Product | Country | Date of suspension |
| --- | --- | --- | --- |
| EU/1/09/527 | Ribavirin Teva Pharma BV | Liechtenstein | 31.8.2013 |
| EU/1/09/527 | Ribavirin Teva Pharma BV | Iceland | 24.7.2013 |

EU-Number

Product

Country

Date of suspension

EU/1/09/527

Ribavirin Teva Pharma BV

Liechtenstein

31.8.2013

EU/1/09/527

Ribavirin Teva Pharma BV

Iceland

24.7.2013

---